Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Blood (2022) 140 (Supplement 1): 1479–1480.

https://doi.org/10.1182/blood-2022-158981

Published: 2022

Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Blood (2018) 132 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2018-99-110555

Published: 2018

Journal Articles

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Blood (2017) 130 (Supplement 1): 2769.

https://doi.org/10.1182/blood.V130.Suppl_1.2769.2769

Published: 2017

Journal Articles

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Larry Mansouri, Daniel Noerenberg, Emma Young, Elena Mylonas, Maysaa Abdulla, Mareike Frick, Fazila Asmar, Viktor Ljungström, Markus Schneider, Kenichi Yoshida, Aron Skaftason, Tatjana Pandzic, Blanca Gonzalez, Anna Tasidou, Nils Waldhueter, Alfredo Rivas-Delgado, Maria Angelopoulou, Marita Ziepert, Christopher Maximilian Arends, Lucile Couronné, Dido Lenze, Claudia D. Baldus, Christian Bastard, Jessica Okosun, Jude Fitzgibbon, Bernd Dörken, Hans G. Drexler, Damien Roos-Weil, Clemens A. Schmitt, Helga D. Munch-Petersen, Thorsten Zenz, Martin-Leo Hansmann, Jonathan C. Strefford, Gunilla Enblad, Olivier A. Bernard, Elisabeth Ralfkiaer, Martin Erlanson, Penelope Korkolopoulou, Magnus Hultdin, Theodora Papadaki, Kirsten Grønbæk, Armando Lopez-Guillermo, Seishi Ogawa, Ralf Küppers, Kostas Stamatopoulos, Niki Stavroyianni, George Kanellis, Andreas Rosenwald, Elias Campo, Rose-Marie Amini, German Ott, Theodoros P. Vassilakopoulos, Michael Hummel, Richard Rosenquist, Frederik Damm

Blood (2016) 128 (23): 2666–2670.

https://doi.org/10.1182/blood-2016-03-704528

Published: 2016

Includes: Supplemental data

Journal Articles

177 lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Blood (2016) 128 (22): 1780.

https://doi.org/10.1182/blood.V128.22.1780.1780

Published: 2016

Journal Articles

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Bjørg Bolstad, MSc, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Jostein Dahle, PhD, Nils Bolstad, MD, Roy Hartvig Larsen, PhD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD

Blood (2015) 126 (23): 5118.

https://doi.org/10.1182/blood.V126.23.5118.5118

Published: 2015

Journal Articles

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Jostein Dahle, PhD, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Bjørg Bolstad, MSc, Nils Bolstad, MD, Anne Tierens, MD PhD, Roy Hartvig Larsen, PhD, Jan Alan Alfheim, MSC, MBA, Jan Delabie, MD PhD, Spetalen Signe, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, MD PhD

Blood (2014) 124 (21): 3094.

https://doi.org/10.1182/blood.V124.21.3094.3094

Published: 2014

Journal Articles

Follicular Lymphoma Survival in Sweden in the Rituximab Era

Henna Riikka Junlén, MD, Stefan Peterson, Eva Kimby, Sandra Lockmer, MD, Ola Linden, MD, Herman Nilsson-Ehle, MD PhD, Martin Erlanson, Hans Hagberg, Anders Rådlund, Oskar Hagberg, Björn E Wahlin, MD PhD

Blood (2014) 124 (21): 1758.

https://doi.org/10.1182/blood.V124.21.1758.1758

Published: 2014

Journal Articles

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

Eva Kimby, M.D., Ph.D., Björn Östenstad, Peter de Nully Brown, Harald Holte, Jr., MD, PhD, Hans Hagberg, Martin Erlanson, Ola Linden, MD, Marie Nordström, MD, PhD, Christer Sundstrom, MD, PhD

Blood (2012) 120 (21): 794.

https://doi.org/10.1182/blood.V120.21.794.794

Published: 2012

Journal Articles

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Blood (2011) 118 (21): 331.

https://doi.org/10.1182/blood.V118.21.331.331

Published: 2011

Journal Articles

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Elisa Jacobsen Pulczynski, Peter Kamper, Unn-Merete Fagerli, Martin Erlanson, Outi Kuittinen, Alexander Fosså, Bjørn Østenstad, Oystein Fluge, Martin Maisenhølder, Hans Hagberg, Mikael Eriksson, Marie Nordstrøm, Sirpa Leppa

Blood (2011) 118 (21): 1602.

https://doi.org/10.1182/blood.V118.21.1602.1602

Published: 2011

Journal Articles

Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Blood (2010) 116 (21): 3565.

https://doi.org/10.1182/blood.V116.21.3565.3565

Published: 2010

Journal Articles

Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Blood (2010) 116 (21): 3566.

https://doi.org/10.1182/blood.V116.21.3566.3566

Published: 2010

Journal Articles

R-CHOEP-14 × 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2–3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18–65 Years.

Harald Holte, MD, PhD, Sirpa LeppÃ¤, MD, PhD, Magnus Bjorkholm, MD, PhD, Øystein Fluge, MD, PhD, Sirkku Jyrkkiö, MD, PhD, Jan Delabie, MD, PhD, Christer Sundstrom, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, Martin Erlanson, MD, PhD, Arne Kolstad, MD, PhD, Alexander Fosså, MD, PhD, Bj∅rn Østenstad, MD, PhD, Eva Löfvenberg, MD, Marie Nordström, MD, PhD, Lars Möller Pedersen, MD, PhD, Harald Anderson, PhD, Mats Jerkeman, MD, PhD, Mikael Eriksson, MD, PhD

Blood (2010) 116 (21): 2805.

https://doi.org/10.1182/blood.V116.21.2805.2805

Published: 2010

Journal Articles

R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2–3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years

Harald Holte, MD, PhD, Sirpa M. Leppa, MD, PhD, Magnus Bjorkholm, MD, PhD, Oystein Fluge, MD, PhD, Sirkku Jyrkkio, MD, PhD, Jan Delabie, MD, PhD, Christer Sundstrom, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Martin Erlanson, MD, PhD, Arne Kolstad, MD, PhD, Alexander Fossa, MD, PhD, Björn Östenstad, MD, PhD, Eva Lofvenberg, MD, PhD, Marie Nordström, MD, PhD, Lars Möller-Pedersen, MD, PhD, Harald Anderson, PhD, Mats Jerkeman, MD, PhD, Mikael Eriksson, MD, PhD

Blood (2008) 112 (11): 3604.

https://doi.org/10.1182/blood.V112.11.3604.3604

Published: 2008

Journal Articles

Genes and Proteins Associated with the Tumor Microenvironment Are Differentially Expressed in Cured Versus Primary Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma.

Johan Linderoth, MD, Patrik Edén, PhD, Mats Ehinger, MD PhD, Jeanette Valcich, Mats Jerkeman, MD PhD, Pär-Ola Bendahl, PhD, Mattias Berglund, PhD, Gunilla Enblad, MD PhD, Martin Erlanson, MD PhD, Göran Roos, MD PhD, Eva Cavallin-Ståhl, MD PhD

Blood (2007) 110 (11): 3171.

https://doi.org/10.1182/blood.V110.11.3171.3171

Published: 2007

Journal Articles

Dose-Dense Induction Followed by Autologous Stem Cell Transplant (ASCT) as 1st Line Treatment in Peripheral T-Cell Lymphomas (PTCL) - A Phase II Study of the Nordic Lymphoma Group (NLG).

Blood (2006) 108 (11): 401.

https://doi.org/10.1182/blood.V108.11.401.401

Published: 2006

Journal Articles

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Gunilla Enblad, Hans Hagberg, Martin Erlanson, Jeanette Lundin, Anja Porwit MacDonald, Roland Repp, Johannes Schetelig, Gernot Seipelt, Anders Österborg

Blood (2004) 103 (8): 2920–2924.

https://doi.org/10.1182/blood-2003-10-3389

Published: 2004

Journal Articles

Expression of Cyclin E and the Cyclin-Dependent Kinase Inhibitor p27 in Malignant Lymphomas—Prognostic Implications

Martin Erlanson, Cajsa Portin, Barbro Linderholm, Jack Lindh, Göran Roos, Göran Landberg

Blood (1998) 92 (3): 770–777.

https://doi.org/10.1182/blood.V92.3.770

Published: 1998

Journal Articles

Telomerase Activity in Hodgkin's Disease

Karl-Fredrik Norrback, Gunilla Enblad, Martin Erlanson, Christer Sundström, Göran Roos

Blood (1998) 92 (2): 567–573.

https://doi.org/10.1182/blood.V92.2.567

Published: 1998

NARROW

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

177 lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Follicular Lymphoma Survival in Sweden in the Rituximab Era

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

R-CHOEP-14 × 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2–3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18–65 Years.

R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2–3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years

Genes and Proteins Associated with the Tumor Microenvironment Are Differentially Expressed in Cured Versus Primary Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma.

Dose-Dense Induction Followed by Autologous Stem Cell Transplant (ASCT) as 1st Line Treatment in Peripheral T-Cell Lymphomas (PTCL) - A Phase II Study of the Nordic Lymphoma Group (NLG).

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Expression of Cyclin E and the Cyclin-Dependent Kinase Inhibitor p27 in Malignant Lymphomas—Prognostic Implications

Telomerase Activity in Hodgkin's Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only